28 Day Repeat Dose in Cystic Fibrosis Patients

Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of QBW251 in Healthy Subjects and Cystic Fibrosis Patients

NCT02190604 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF)

NCT06526923 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis

NCT03911713 ·Status: COMPLETED ·Phase: PHASE2

A Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis

NCT03056989 ·Status: COMPLETED ·Phase: PHASE1

Safety, Pharmacokinetics and Pharmacodynamics Study of Inhaled QBW276 in Patients With Cystic Fibrosis

NCT02566044 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Dose Escalation Study of KB001 in Cystic Fibrosis Patients Infected With Pseudomonas Aeruginosa

NCT00638365 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Study of the Dosing, Efficacy, and Safety of Oral Cysteamine in Adult Patients With Cystic Fibrosis Exacerbations

NCT03000348 ·Status: COMPLETED ·Phase: PHASE2

Safety Study of Inhaled 552-02 in Cystic Fibrosis Patients

NCT00274313 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

First Study of Oral Cysteamine in Cystic Fibrosis

NCT02212431 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Study to Evaluate Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Adults With Cystic Fibrosis

NCT03029455 ·Status: COMPLETED ·Phase: PHASE1

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis

NCT05090904 ·Status: COMPLETED ·Phase: PHASE2

Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 (Lenabasum) in Cystic Fibrosis

NCT02465450 ·Status: COMPLETED ·Phase: PHASE2

Miglustat in Cystic Fibrosis

NCT00742092 ·Status: COMPLETED ·Phase: PHASE2

Safety and Tolerability Study of Liquid Alpha1 Proteinase Inhibitor (API) in Subjects With Cystic Fibrosis

NCT01347190 ·Status: COMPLETED ·Phase: PHASE1

Safety and PK Study of CC-90001 in Subjects With Pulmonary Fibrosis

NCT02510937 ·Status: COMPLETED ·Phase: PHASE1

A Study to Evaluate Efficacy of Ivacaftor in Subjects With Cystic Fibrosis Who Have a 3849 + 10KB C→T or D1152H CFTR Mutation

NCT03068312 ·Status: COMPLETED ·Phase: PHASE3

A Study to Evaluate Safety, PK and PD of FDL169 in Cystic Fibrosis Subjects

NCT03093714 ·Status: COMPLETED ·Phase: PHASE1

Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.

NCT04038710 ·Status: COMPLETED

An Efficacy and Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis

NCT03229252 ·Status: COMPLETED ·Phase: PHASE2

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QAU145 in Patients With Cystic Fibrosis

NCT00506792 ·Status: COMPLETED ·Phase: PHASE2

A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF

NCT06237335 ·Status: RECRUITING ·Phase: PHASE2

Study for Evaluating the Real Use of Inhaled Aztreonam Lysine in Patients With Cystic Fibrosis

NCT03607396 ·Status: UNKNOWN

Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic Fibrosis

NCT01684410 ·Status: COMPLETED ·Phase: PHASE2

Phase 1b Safety, Tolerability, and PK Study to Assess GS-5737 in Subjects With CF

NCT01840735 ·Status: COMPLETED ·Phase: PHASE1

Testing Drug Efficacy in Cystic Fibrosis Through N-of-1 Trials

NCT04580368 ·Status: RECRUITING ·Phase: NA